Login
$JANX
$11.12 +$0.20 (1.83%) After hours

$JANX SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts

31 Jul 2026 Form 4: Campbell David Alan, Director

Gave 123,840 shares as a gift

28 Jul 2026 SCHEDULE 13G/A
10 Jul 2026 Form 4: Campbell David Alan, Director

Received 7,000 shares by exercise or conversion ($29.5K)

23 Jun 2026 8-K: Other Events

On June 23, 2026, William Go, M.D., Ph.D. departed as Chief Medical Officer of Janux Therapeutics, Inc. (the "Company") under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Co...

12 Jun 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (Right to Buy)

12 Jun 2026 Form 4: Simson Jake, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

12 Jun 2026 Form 4: Hernday Natasha, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

12 Jun 2026 Form 4: Dobmeier Eric, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Janux Therapeutics, Inc. (the “Company”) held the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting, 60,961,546 shares of common stock wer...

12 Jun 2026 Form 4: Kung Winston, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

12 Jun 2026 Form 4: Capps Vickie L, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

12 Jun 2026 Form 4: Barrett Ronald W, Director

Received 5,500 shares as a grant or award · Granted 15,500 Stock Option (right to buy)

04 Jun 2026 Form 4: Doyle Janeen Noel, Chief Corp. & Bus. Dev. Ofcr

Sold 4,059 shares ($56.9K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support